Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование пембролизумаба с поддерживающей терапией олапарибом или поддерживающей терапией пеметрекседом при лечении первой линии (1 л) метастатического неплоскоклеточного немелкоклеточного рака легкого (НМРЛ) (MK-7339-006, KEYLYNK-006)

3 сентября 2026 г. обновлено: Merck Sharp & Dohme LLC

Исследование фазы 3 пембролизумаба в комбинации с пеметрекседом/платиной (карбоплатином или цисплатином) с последующим применением пембролизумаба и поддерживающей терапии олапарибом по сравнению с поддерживающей терапией пеметрекседом в терапии первой линии участников с метастатическим неплоскоклеточным немелкоклеточным раком легкого

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).

Обзор исследования

Подробное описание

This study has 2 phases: an Induction Phase of up to ~4 Cycles (up to ~12 weeks [cycle =3 weeks]) and a Maintenance Phase of up to ~31 cycles of pembrolizumab (cycle = 3 weeks]); total pembrolizumab treatment duration will be up to ~35 cycles (up to ~2 years). In the Induction Phase, participants receive pembrolizumab plus pemetrexed plus platinum (carboplatin or cisplatin, at the investigator's discretion). In the Maintenance Phase, participants with a partial or complete disease response or with stable disease after completing four cycles of induction therapy and who meet eligibility criteria will be randomly assigned to receive pembrolizumab plus maintenance olaparib OR pembrolizumab plus maintenance pemetrexed. In the Maintenance Phase, participants receive pembrolizumab for up to 31 cycles (cycle = 3 weeks) plus maintenance olaparib OR maintenance pemetrexed until progressive disease (PD), intolerable toxicities, or physician decision.

Qualified participants in each study arm of the maintenance phase (Pembrolizumab plus Olaparib and Pembrolizumab plus Pemetrexed) who complete up to ~35 cycles of pembrolizumab (up to ~2 years [cycle =3 weeks]) may be eligible to receive a second course of pembrolizumab for up to ~17 cycles (up to ~1 additional year). Per protocol, response or progression during the second pembrolizumab course will not be counted towards patient reported outcomes (PROs) or efficacy outcome measures and adverse events during the second pembrolizumab course will not be counted towards safety outcome measures.

Тип исследования

Интервенционный

Регистрация (Действительный)

1003

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

    • New South Wales
      • Liverpool, New South Wales, Австралия, 2170
        • Liverpool Hospital ( Site 1201)
      • Wollongong, New South Wales, Австралия, 2500
        • Southern Medical Day Care Centre ( Site 1200)
    • Queensland
      • Townsville, Queensland, Австралия, 4814
        • Townsville General Hospital ( Site 1202)
    • Victoria
      • Clayton, Victoria, Австралия, 3168
        • Monash Cancer Centre ( Site 1205)
      • Vienna, Австрия, 1210
        • Krankenhaus Nord - Klinik Floridsdorf ( Site 1300)
    • State of Vienna
      • Vienna, State of Vienna, Австрия, 1145
        • Social Medical Center - Otto Wagner Hospital ( Site 1301)
    • Tyrol
      • Innsbruck, Tyrol, Австрия, 6020
        • Innsbruck LKH ( Site 1302)
    • Upper Austria
      • Linz, Upper Austria, Австрия, 4020
        • Ordensklinikum Linz GmbH Elisabethinen ( Site 1307)
      • Wels, Upper Austria, Австрия, 4600
        • Klinikum Wels-Grieskirchen ( Site 1304)
      • Córdoba, Аргентина, X5004SHP
        • Clínica Universitaria Reina Fabiola ( Site 0505)
      • Santa Fe, Аргентина, S3000AOL
        • Sanatorio Privado San Geronimo S.R.L ( Site 0510)
    • Buenos Aires
      • Bahía Blanca, Buenos Aires, Аргентина, B8001HXM
        • Hospital Italiano Regional del Sur ( Site 0509)
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Аргентина, C1199ABB
        • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0511)
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Аргентина, C1280AEB
        • Hospital Britanico de Buenos Aires ( Site 0500)
    • Córdoba Province
      • Río Cuarto, Córdoba Province, Аргентина, X5800AEV
        • Instituto Medico Rio Cuarto ( Site 0501)
    • Santa Fe Province
      • Rosario, Santa Fe Province, Аргентина, S2000KZE
        • Centro Oncológico de Rosario ( Site 0507)
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Аргентина, T4000IAK
        • Centro Medico San Roque ( Site 0506)
      • Rio de Janeiro, Бразилия, 20231-050
        • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0203)
      • São Paulo, Бразилия, 01246-000
        • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0200)
      • São Paulo, Бразилия, 01321-001
        • BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0214)
      • São Paulo, Бразилия, 01321-001
        • Hospital Paulistano - Amil Clinical Research ( Site 0207)
    • Ceará
      • Fortaleza, Ceará, Бразилия, 60351-030
        • Instituto do Cancer do Ceara ( Site 0201)
    • Estado de Bahia
      • Salvador, Estado de Bahia, Бразилия, 41253-190
        • Hospital Sao Rafael ( Site 0212)
    • Pará
      • Belém, Pará, Бразилия, 66053-000
        • Oncologica do Brasil ( Site 0210)
    • Rio Grande do Sul
      • Bento Gonçalves, Rio Grande do Sul, Бразилия, 95700-000
        • Hospital Tacchini ( Site 0208)
      • Porto Alegre, Rio Grande do Sul, Бразилия, 90050-170
        • Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 0209)
      • Santa Cruz do Sul, Rio Grande do Sul, Бразилия, 96810-110
        • Saint Gallen Instituto de Oncologia ( Site 0206)
    • Santa Catarina
      • Florianópolis, Santa Catarina, Бразилия, 88020-210
        • YNOVA Pesquisa Clinica ( Site 0215)
      • Itajaí, Santa Catarina, Бразилия, 88301-220
        • Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0202)
      • Joinville, Santa Catarina, Бразилия, 89201-260
        • Centro de Hematologia e Oncologia ( Site 0205)
    • São Paulo
      • Sao Jose Rio Preto, São Paulo, Бразилия, 15080-000
        • Hospital de Base de Sao Jose de Rio Preto ( Site 0204)
      • Hamburg, Германия, 22087
        • Katholisches Marienkrankenhaus gGmbH ( Site 1522)
    • Bavaria
      • Aschaffenburg, Bavaria, Германия, 63739
        • Studienzentrum Aschaffenburg ( Site 1525)
      • Munich, Bavaria, Германия, 80336
        • Klinikum der LMU ( Site 1500)
      • Munich, Bavaria, Германия, 81925
        • Klinikum Bogenhausen Staedt. Klinikum Muenchen GmbH ( Site 1523)
      • Regensburg, Bavaria, Германия, 93053
        • Universitaetsklinikum Regensburg ( Site 1512)
      • Würzburg, Bavaria, Германия, 97074
        • Klinikum Wuerzburg Mitte gGmbH ( Site 1509)
    • Hesse
      • Frankfurt am Main, Hesse, Германия, 60590
        • Universitaetsklinikum Frankfurt ( Site 1513)
      • Immenhausen, Hesse, Германия, 34376
        • Pneumologische Lehrklinik Universitaet Goettingen ( Site 1501)
    • Lower Saxony
      • Göttingen, Lower Saxony, Германия, 37075
        • Universitaetsmedizin Goettingen ( Site 1507)
    • North Rhine-Westphalia
      • Bonn, North Rhine-Westphalia, Германия, 53127
        • Universitaetsklinikum Bonn ( Site 1524)
      • Essen, North Rhine-Westphalia, Германия, 45136
        • Kliniken Essen Mitte ( Site 1517)
    • Rhineland-Palatinate
      • Koblenz, Rhineland-Palatinate, Германия, 56068
        • InVo-Institut fuer Versorgungsforschung in der Onkologie ( Site 1514)
    • Thuringia
      • Erfurt, Thuringia, Германия, 99089
        • Helios Klinikum Erfurt GmbH ( Site 1502)
      • Barcelona, Испания, 08003
        • Hospital del Mar ( Site 1702)
      • Seville, Испания, 41014
        • Hospital Universitario Nuestra Senora de Valme ( Site 1703)
      • Zaragoza, Испания, 50009
        • Hospital Clinico Lozano Blesa ( Site 1700)
    • Madrid
      • Pozuelo de Alarcón, Madrid, Испания, 28223
        • Hospital Universitario Quiron Madrid ( Site 1701)
    • Valenciana, Comunitat
      • Valencia, Valenciana, Comunitat, Испания, 46010
        • Hospital Clinico Universitario de Valencia ( Site 1706)
    • British Columbia
      • North Vancouver, British Columbia, Канада, V7L 2L7
        • Lions Gate Hospital ( Site 0106)
      • Victoria, British Columbia, Канада, V8R 6V5
        • BC Cancer - Victoria ( Site 0109)
    • Nova Scotia
      • Halifax, Nova Scotia, Канада, B3H 2Y9
        • Queen Elizabeth II Health Sciences Centre ( Site 0107)
    • Ontario
      • Greater Sudbury, Ontario, Канада, P3E 5J1
        • Health Sciences North Research Institute ( Site 0115)
      • Kitchener, Ontario, Канада, N2G 1G3
        • Waterloo Regional Health Network (WRHN) ( Site 0117)
      • Newmarket, Ontario, Канада, L3Y 2P9
        • Stronach Regional Cancer Centre ( Site 0101)
    • Quebec
      • Greenfield Park, Quebec, Канада, J4V 2H1
        • CISSS de la Monteregie-Centre ( Site 0114)
      • Montreal, Quebec, Канада, H3T 1M5
        • CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0110)
      • Montreal, Quebec, Канада, H2X 3E4
        • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0105)
      • Rimouski, Quebec, Канада, G5L 5T1
        • Centre de Sante et des Services Sociaux de Rimouski-Neigette ( Site 0104)
      • Sherbrooke, Quebec, Канада, J1H 5N4
        • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0103)
    • Antioquia
      • Medellín, Antioquia, Колумбия, 050030
        • Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0604)
    • Atlántico
      • Barranquilla, Atlántico, Колумбия, 080020
        • Clinica de la Costa S.A.S. ( Site 0608)
    • Bogota D.C.
      • Bogotá, Bogota D.C., Колумбия, 110221
        • Administradora Country S.A. ( Site 0603)
      • Bogotá, Bogota D.C., Колумбия, 111321
        • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 0601)
      • Wellington, Новая Зеландия, 6021
        • Capital & Coast District Health Board - Wellington Hospital ( Site 1101)
    • Manawatu-Wanganui
      • Palmerston North, Manawatu-Wanganui, Новая Зеландия, 4414
        • MidCentral DHB Palmerston North Hospital ( Site 1102)
    • Greater Poland Voivodeship
      • Konin, Greater Poland Voivodeship, Польша, 62-500
        • Przychodnia Lekarska Komed ( Site 2416)
      • Poznan, Greater Poland Voivodeship, Польша, 61-693
        • MED-POLONIA Sp. z o.o. ( Site 2419)
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Польша, 31-202
        • Krakowski Szpital Specjalistyczny im Jana Pawla II ( Site 2420)
    • Lower Silesian Voivodeship
      • Zgorzelec, Lower Silesian Voivodeship, Польша, 59-900
        • Wielospecjalistyczny Szpital SPZOZ w Zgorzelcu ( Site 2404)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Польша, 02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2418)
    • Silesian Voivodeship
      • Racibórz, Silesian Voivodeship, Польша, 47-400
        • Szpital Rejonowy im. dr Jozefa Rostka ( Site 2402)
    • Warmian-Masurian Voivodeship
      • Olsztyn, Warmian-Masurian Voivodeship, Польша, 10-357
        • Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie ( Site 2417)
    • Moscow
      • Moscow, Moscow, Россия, 115478
        • Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 2000)
      • Moscow, Moscow, Россия, 119991
        • First Moscow State Medical University n.a. I.M.Sechenov ( Site 2024)
      • Moscow, Moscow, Россия, 125284
        • Moscow Research Oncology Institute named after P.A. Hertsen ( Site 2009)
      • Moscow, Moscow, Россия, 125367
        • FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 2006)
    • Moscow Oblast
      • Balashikha, Moscow Oblast, Россия, 143900
        • Moscow Regional Oncological Dispensary ( Site 2028)
    • Nizhny Novgorod Oblast
      • Nizhny Novgorod, Nizhny Novgorod Oblast, Россия, 603081
        • Nizhniy Novgorod Region Oncology Dispensary ( Site 2026)
    • Omsk Oblast
      • Omsk, Omsk Oblast, Россия, 644013
        • Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site 2010)
    • Samara Oblast
      • Samara, Samara Oblast, Россия, 443031
        • SBHI Samara Regional Clinical Oncology Dispensary ( Site 2016)
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Россия, 194291
        • SBHI Leningrad Regional Clinical Hospital ( Site 2002)
      • Saint Petersburg, Sankt-Peterburg, Россия, 195271
        • SPb Central Clinical Railway Hospital ( Site 2003)
      • Saint Petersburg, Sankt-Peterburg, Россия, 197758
        • National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 2004)
      • Saint Petersburg, Sankt-Peterburg, Россия, 198255
        • SPb SBHI City Clinical Oncological Dispensary ( Site 2001)
    • Tatarstan, Respublika
      • Kazan', Tatarstan, Respublika, Россия, 420029
        • Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 2021)
      • Brasov, Румыния, 500152
        • Spitalul PDR Medlife ( Site 2509)
    • Bucharest
      • Bucharest, Bucharest, Румыния, 013823
        • MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 2502)
    • Cluj
      • Cluj-Napoca, Cluj, Румыния, 407280
        • S.C. Radiotherapy Center Cluj S.R.L ( Site 2507)
      • Cluj-Napoca, Cluj, Румыния, 400015
        • Cardiomed SRL Cluj-Napoca ( Site 2504)
    • Constanța County
      • Ovidiu, Constanța County, Румыния, 905900
        • Ovidius Clinical Hospital OCH ( Site 2501)
    • Dolj
      • Craiova, Dolj, Румыния, 200542
        • S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2508)
    • Timiș County
      • Timișoara, Timiș County, Румыния, 300239
        • Policlinica Oncomed SRL ( Site 2505)
      • Birmingham, Соединенное Королевство, B9 5SS
        • Birmingham Heartlands Hospital ( Site 1910)
    • London, City of
      • London, London, City of, Соединенное Королевство, EC1M 6BQ
        • Barts Health NHS Trust - St Bartholomew s Hospital ( Site 1923)
      • London, London, City of, Соединенное Королевство, SW10 9NH
        • Chelsea and Westminster Hospital ( Site 1901)
    • Suffolk
      • Bury St Edmunds, Suffolk, Соединенное Королевство, IP33 2QZ
        • West Suffolk Hospitals NHS Trust ( Site 1919)
    • United Kingdom
      • Edinburgh, United Kingdom, Соединенное Королевство, EH4 2XU
        • Western General Hospital, Edinburgh ( Site 1924)
    • Wales
      • Swansea, Wales, Соединенное Королевство, SA2 8QA
        • Singleton Hospital ( Site 1909)
    • Worcestershire
      • Colchester, Worcestershire, Соединенное Королевство, CO4 5JL
        • Colchester General Hospital ( Site 1911)
    • Alabama
      • Birmingham, Alabama, Соединенные Штаты, 35205
        • Alabama Oncology Bruno Cancer Center ( Site 0001)
      • Muscle Shoals, Alabama, Соединенные Штаты, 35661
        • Northwest Alabama Cancer Center, PC ( Site 0002)
    • California
      • Burbank, California, Соединенные Штаты, 91505
        • Disney Family Cancer Center ( Site 0005)
    • Florida
      • Boca Raton, Florida, Соединенные Штаты, 33486
        • Boca Raton Regional Hospital ( Site 0018)
      • Orange City, Florida, Соединенные Штаты, 32763
        • Mid-Florida Cancer Centers ( Site 0022)
      • Tampa, Florida, Соединенные Штаты, 33612
        • Moffitt Cancer Center ( Site 0024)
    • Georgia
      • Columbus, Georgia, Соединенные Штаты, 31904
        • Columbus Regional Research Institute ( Site 0098)
    • Illinois
      • Chicago, Illinois, Соединенные Штаты, 60608
        • Mount Sinai Hospital Medical Center ( Site 0032)
      • Rolling Meadows, Illinois, Соединенные Штаты, 60008
        • Oncology of Northshore ( Site 0033)
    • Indiana
      • Merrillville, Indiana, Соединенные Штаты, 46410
        • Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0036)
    • Maryland
      • Baltimore, Maryland, Соединенные Штаты, 21239
        • Medstar Good Samaritan Hospital ( Site 0040)
    • Michigan
      • Detroit, Michigan, Соединенные Штаты, 48201
        • Barbara Ann Karmanos Cancer Institute ( Site 0041)
    • Mississippi
      • Hattiesburg, Mississippi, Соединенные Штаты, 39401
        • Hattiesburg Clinic ( Site 0045)
    • Montana
      • Billings, Montana, Соединенные Штаты, 59102
        • Frontier Oncology ( Site 0080)
      • Bozeman, Montana, Соединенные Штаты, 59715
        • Bozeman Health Deaconness Cancer Center ( Site 0046)
    • North Carolina
      • Cary, North Carolina, Соединенные Штаты, 27518
        • Waverly Hematology Oncology ( Site 0081)
    • Tennessee
      • Knoxville, Tennessee, Соединенные Штаты, 37920
        • University of Tennessee Medical Center Knoxville ( Site 0060)
      • Knoxville, Tennessee, Соединенные Штаты, 37916
        • Thompson Cancer Survival Center ( Site 2812)
    • Texas
      • The Woodlands, Texas, Соединенные Штаты, 77380
        • Renovatio Clinical ( Site 0062)
    • Washington
      • Spokane Valley, Washington, Соединенные Штаты, 99216
        • Cancer Care Northwest ( Site 0071)
      • Kaohsiung City, Тайвань, 833
        • Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0907)
      • Taichung, Тайвань, 40447
        • China Medical University Hospital ( Site 0904)
      • Tainan, Тайвань, 70457
        • National Cheng Kung University Hospital ( Site 0905)
      • Taipei, Тайвань, 104
        • Mackay Memorial Hospital ( Site 0902)
      • Taipei, Тайвань, 100
        • National Taiwan University Hospital ( Site 0900)
      • Taoyuan, Тайвань, 333
        • Chang Gung Medical Foundation.Linkou Branch ( Site 0903)
      • Adana, Турция (Туркие), 01120
        • Baskent Unv. Adana Uyg. ve Arast. Hastanesi ( Site 2101)
      • Ankara, Турция (Туркие), 06500
        • Gazi Universitesi Tip Fakultesi ( Site 2104)
      • Ankara, Турция (Туркие), 06800
        • Ankara Bilkent Sehir Hastanesi ( Site 2105)
      • Istanbul, Турция (Туркие), 34093
        • Bezmialem Vakif Univ. Tıp Fakultesi Hastanesi Tibbi Onkoloji Bolumu ( Site 2107)
      • Istanbul, Турция (Туркие), 34722
        • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2103)
      • Izmir, Турция (Туркие), 35040
        • Ege Universitesi Tip Fakultesi ( Site 2109)
      • Kayseri, Турция (Туркие), 38039
        • Erciyes Universitesi Tip Fakultesi ( Site 2108)
      • Samsun, Турция (Туркие), 55139
        • Ondokuz Mayıs Universitesi-Oncology department ( Site 2106)
    • Tekirdas
      • Tekirdağ, Tekirdas, Турция (Туркие), 59100
        • Namik Kemal Universitesi Tip Fakultesi ( Site 2100)
      • Kyiv, Украина, 03115
        • Kyiv City Clinical Oncology Centre ( Site 2210)
    • Cherkasy Oblast
      • Cherkasy, Cherkasy Oblast, Украина, 18009
        • Cherkasy Regional Oncology Dispensary ( Site 2211)
    • Dnipropetrovsk Oblast
      • Dnipro, Dnipropetrovsk Oblast, Украина, 49102
        • Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 2201)
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk, Ivano-Frankivsk Oblast, Украина, 76018
        • MI Precarpathian Clinical Oncology Center ( Site 2204)
    • Kharkiv Oblast
      • Kharkiv, Kharkiv Oblast, Украина, 61024
        • Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2212)
      • Kharkiv, Kharkiv Oblast, Украина, 61070
        • CNPE "Regional Center of Oncology"-Thoracic organs ( Site 2205)
    • Kirovohrad Oblast
      • Kropyvnitskiy, Kirovohrad Oblast, Украина, 25006
        • PP PPC Acinus Medical and Diagnostic Centre ( Site 2209)
    • Kyivska Oblast
      • Khodosovka, Kyivska Oblast, Украина, 08173
        • Medical Center Asklepion LLC ( Site 2234)
      • Kyiv, Kyivska Oblast, Украина, 03126
        • Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2213)
      • Kyiv, Kyivska Oblast, Украина, 03039
        • Medical Center Verum ( Site 2230)
    • Odesa Oblast
      • Odesa, Odesa Oblast, Украина, 65055
        • MI Odessa Regional Oncological Centre ( Site 2208)
    • Zakarpattia Oblast
      • Uzhhorod, Zakarpattia Oblast, Украина, 88000
        • Central City Clinical Hospital ( Site 2207)
    • Ain
      • Vandœuvre-lès-Nancy, Ain, Франция, 54519
        • Institut De Cancerologie De Lorraine ( Site 1409)
    • Aisne
      • Chauny, Aisne, Франция, 02300
        • Centre Hospitalier De Chauny ( Site 1411)
    • Calvados
      • Caen, Calvados, Франция, 14033
        • CHU Caen ( Site 1406)
    • Maine-et-Loire
      • Angers, Maine-et-Loire, Франция, 49100
        • CHU Angers ( Site 1405)
    • Moselle
      • Vantoux, Moselle, Франция, 57070
        • Hopital Robert Schuman ( Site 1402)
    • Puy-de-Dome
      • Clermont-Ferrand, Puy-de-Dome, Франция, 63011
        • Centre Jean Perrin ( Site 1407)
    • Pyrenees-Atlantiques
      • Pau, Pyrenees-Atlantiques, Франция, 64000
        • Centre Hospitalier de Pau ( Site 1412)
    • Seine-Maritime
      • Rouen, Seine-Maritime, Франция, 76000
        • CHU de Rouen ( Site 1403)
    • Val-de-Marne
      • Saint-Mandé, Val-de-Marne, Франция, 94163
        • Hopital d'Instruction des Armees Begin ( Site 1413)
      • Seoul, Южная Корея, 03080
        • Seoul National University Hospital ( Site 1000)
      • Seoul, Южная Корея, 08308
        • Korea University Guro Hospital ( Site 1008)
    • Kyonggi-do
      • Goyang-si, Kyonggi-do, Южная Корея, 10408
        • National Cancer Center ( Site 1006)
      • Suwon, Kyonggi-do, Южная Корея, 16247
        • The Catholic University of Korea St. Vincent s Hospital ( Site 1003)
      • Suwon, Kyonggi-do, Южная Корея, 16499
        • Ajou University Hospital ( Site 1004)
    • Kyongsangnam-do
      • Jinju, Kyongsangnam-do, Южная Корея, 52727
        • Gyeongsang National University Hospital ( Site 1005)
    • North Chungcheong
      • Cheongju-si, North Chungcheong, Южная Корея, 28644
        • Chungbuk National University Hospital ( Site 1002)
    • Seoul
      • Songpa-gu, Seoul, Южная Корея, 05505
        • Asan Medical Center ( Site 1007)
      • Fukuoka, Япония, 8108563
        • National Hospital Organization Kyushu Medical Center ( Site 0805)
      • Niigata, Япония, 951-8566
        • Niigata Cancer Center Hospital ( Site 0808)
      • Okayama, Япония, 700-8558
        • Okayama University Hospital ( Site 0810)
      • Osaka, Япония, 541-8567
        • Osaka International Cancer Institute ( Site 0809)
      • Tokyo, Япония, 135-8550
        • Cancer Institute Hospital of JFCR ( Site 0800)
    • Aichi-ken
      • Nagoya, Aichi-ken, Япония, 460-0001
        • National Hospital Organization Nagoya Medical Center ( Site 0806)
      • Nagoya, Aichi-ken, Япония, 464-8681
        • Aichi Cancer Center ( Site 0803)
    • Chiba
      • Kashiwa, Chiba, Япония, 2778577
        • National Cancer Center Hospital East ( Site 0801)
    • Ishikawa-ken
      • Kanazawa, Ishikawa-ken, Япония, 920-8641
        • Kanazawa University Hospital ( Site 0811)
    • Kanagawa
      • Yokohama, Kanagawa, Япония, 241-8515
        • Kanagawa Cancer Center ( Site 0807)
    • Miyagi
      • Sendai, Miyagi, Япония, 981-0914
        • Sendai Kousei Hospital ( Site 0812)
    • Osaka
      • Hirakata, Osaka, Япония, 573-1191
        • Kansai Medical University Hospital ( Site 0804)
      • Sakai, Osaka, Япония, 591-8555
        • National Hospital Organization Kinki-chuo Chest Medical Center ( Site 0813)
    • Shizuoka
      • Suntogun, Shizuoka, Япония, 411-8777
        • Shizuoka Cancer Center ( Site 0802)

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  1. Have a histologically or cytologically confirmed diagnosis nonsquamous NSCLC.

  2. Have stage IV nonsquamous NSCLC.

  3. Have confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or Proto-oncogene tyrosine-protein kinase (ROS1)-directed therapy is not indicated.

  4. Have measurable disease based on RECIST 1.1.

  5. Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated.

    Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase. Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time.

  6. Have a life expectancy of at least 3 months.

  7. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status assessed within 7 days prior to the administration of study intervention.

  8. Have not received prior systemic treatment for their advanced/metastatic NSCLC.

  9. Have adequate organ function.

  10. Male and female participants who are not pregnant and of childbearing potential must follow contraceptive guidance during the treatment period and for 180 days afterwards.

  11. Male participants must refrain from donating sperm, and female participants must refrain from donating eggs to others or freeze/store for her own use during the treatment period and for 180 days afterwards.

Exclusion Criteria:

  1. Has predominantly squamous cell histology NSCLC.
  2. Has a known additional malignancy that is progressing or has progressed within the past 3 years requiring active treatment.
  3. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  4. Has a severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
  5. Has a known hypersensitivity to any components or excipients of cisplatin, carboplatin, pemetrexed, or olaparib.
  6. Has an active autoimmune disease that has required systemic treatment in past 2 years.
  7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
  8. Has a known history of human immunodeficiency virus (HIV) infection, a known history of hepatitis B infection, or known active hepatitis C virus infection.
  9. Has interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment.
  10. Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor.
  11. Has received prior therapy with an agent directed to programmed cell death ligand 1 (PD-L1), anti PD-L2, or directed to a stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
  12. Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
  13. Has completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib

For the Induction Phase, participants receive 4 cycles (up to ~12 weeks [cycle = 3 weeks]): pembrolizumab 200 mg intravenous (IV) on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of each cycle (Cycles 1 through 4).

If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. The participant can continue to receive maintenance olaparib until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to ~35 cycles (up to ~2 years [cycle = 3 weeks]).

IV infusion

Другие имена:
  • МК-3475
  • КЕЙТРУДА®

Oral Tablet

Другие имена:
  • ЛИНПАРЗА®

IV infusion

Другие имена:
  • ПЛАТИНОЛ®
  • ПЛАТИНОЛ®-AQ

IV infusion

Другие имена:
  • ПАРАПЛАТИН®

IV infusion

Другие имена:
  • АЛИМТА®
Активный компаратор: Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed

For the Induction Phase, participants receive 4 cycles (up to ~12 weeks [cycle = 3 weeks]): pembrolizumab 200 mg IV on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin AUC 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of each cycle (Cycles 1 through 4).

If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance pemetrexed 500 mg/m^2 IV on Day 1 of each 3-week cycle. The participant can continue to receive maintenance pemetrexed until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to ~35 cycles (up to ~2 years [cycle = 3 weeks]).

IV infusion

Другие имена:
  • МК-3475
  • КЕЙТРУДА®

IV infusion

Другие имена:
  • ПЛАТИНОЛ®
  • ПЛАТИНОЛ®-AQ

IV infusion

Другие имена:
  • ПАРАПЛАТИН®

IV infusion

Другие имена:
  • АЛИМТА®

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Progression-free Survival (PFS)
Временное ограничение: Up to ~31 months

PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was analyzed by the non-parametric Kaplan-Meier (K-M) method. The protocol specified final analysis of PFS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~31 months
Overall Survival (OS)
Временное ограничение: Up to ~51 months

OS was defined as the time from randomization to death due to any cause. OS was analyzed by the non-parametric K-M method. Participants without documented death at the time of analyses were censored at the date of last known to be alive. The protocol specified final analysis of OS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~51 months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Number of Participants Who Experience One or More Adverse Events (AEs)
Временное ограничение: Up to ~5 years

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.

Up to ~5 years
Number of Participants Who Discontinue Study Treatment Due to an AE
Временное ограничение: Up to ~5 years

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.

Up to ~5 years
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 and 30) Scale Score
Временное ограничение: Baseline and Week 24

EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
Time to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score
Временное ограничение: Up to ~24 months

EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome was not done in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score
Временное ограничение: Baseline and Week 24

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 cough (Item 1) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-LC13 Cough (Item 1) Scale Score
Временное ограничение: Up to ~24 months

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 1). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
Временное ограничение: Baseline and Week 24

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 chest pain (Item 10) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
Временное ограничение: Up to ~24 months

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in chest pain (Item 10). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
Временное ограничение: Baseline and Week 24

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
Временное ограничение: Up to ~24 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
Временное ограничение: Baseline and Week 24

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Baseline and Week 24
TTD in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
Временное ограничение: Up to ~24 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Up to ~24 months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Следователи

  • Директор по исследованиям: Medical Director, Merck Sharp & Dohme LLC

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Полезные ссылки

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

28 июня 2019 г.

Первичное завершение (Действительный)

7 февраля 2024 г.

Завершение исследования (Действительный)

30 января 2026 г.

Даты регистрации исследования

Первый отправленный

3 июня 2019 г.

Впервые представлено, что соответствует критериям контроля качества

3 июня 2019 г.

Первый опубликованный (Действительный)

6 июня 2019 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

28 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

3 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • 7339-006
  • 2018 (Грант/контракт NIH США)
  • MK-7339-006 (Другой идентификатор: MSD)
  • KEYLYNK-006 (Другой идентификатор: MSD)
  • 194895 (Идентификатор реестра: JAPIC-CTI)
  • 2018-004720-11 (Номер EudraCT)
  • U1111-1300-7107 (Идентификатор реестра: UTN)
  • 2023-509774-40-00 (Идентификатор реестра: EU CT)
  • 2023 (Грант/контракт NIH США)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться